Global Antithrombin Market Share Grows Steadily at a CAGR of 4.95%

A major factor driving the growth of the global antithrombin market is the increasing awareness and improved detection of antithrombin deficiency, supported by advancements in genetic testing and coagulation screening methods. Early and accurate diagnosis has resulted in a surge in the clinical use of antithrombin, particularly in high-risk medical scenarios such as neonatal care and complex surgical procedures. Its vital role in preventing thrombosis during operations like cardiopulmonary bypass and organ transplants continues to boost its demand.

In addition, supportive regulatory policies for rare disease treatments are playing a fundamental role in market expansion. Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) provide incentives like orphan drug status, tax benefits, and market exclusivity, encouraging pharmaceutical companies to invest in antithrombin development. Together, these factors, including advanced diagnostics, increased surgical usage, and favorable regulatory support, are propelling the market forward, especially in developed countries and gradually across emerging healthcare markets in Asia-Pacific and Latin America.

Market Dynamics

Rising incidence of thrombotic disorders drives the global market

The rising global incidence of thrombotic disorders is a key aspect augmenting the growth of the global market. Lifestyle-related factors such as physical inactivity, an aging population, obesity, and cancer are significantly contributing to the increasing prevalence of conditions like venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE).

• In major markets including the U.S., U.K., Germany, France, Italy, Spain, Canada, and Japan, the number of diagnosed VTE cases is anticipated to grow from 1.12 million in 2015 to approximately 1.35 million by 2025, reflecting an annual growth rate of around 2.1%. Diagnosed DVT cases alone are projected to increase from 801,472 in 2015 to 977,234 by 2025, with an estimated annual growth of 2.2%.

This consistent increase underscores the rising need for anticoagulant treatments, particularly antithrombin. Moreover, its expanding use in surgical interventions and critical care settings further enhances its clinical significance and market prospects.

Strategic partnerships and acquisitions create tremendous opportunities

Strategic alliances and acquisitions are opening up fresh growth opportunities in the global pharmaceutical market. Companies are increasingly collaborating to speed up research, strengthen supply chains, and broaden their product offerings. These partnerships are particularly vital in tackling rare and complex diseases, where development costs are high and timelines are lengthy.

• As an example, in February 2022, Grifols entered into a global partnership and licensing agreement with Endpoint Health to advance and commercialize Antithrombin III (AT-III) as a potential treatment for sepsis. Under the agreement, Grifols will provide AT-III and contribute up to $25 million toward clinical development, while Endpoint Health will lead a Phase II trial using its AI-driven companion diagnostic technology and retain worldwide commercial rights (excluding China).

These collaborations foster innovation, ease financial pressures, and accelerate market entry, laying a strong foundation for broader adoption of antithrombin in critical care settings.

Regional Insights

The North American antithrombin market is experiencing significant growth due to the surging prevalence of thrombotic disorders and advancements in biotechnology. According to the CDC, approximately 900,000 people are affected by venous thromboembolism (VTE) annually in the U.S., highlighting the growing need for effective anticoagulant therapies. Increased awareness and improved screening for antithrombin deficiency have also contributed to early diagnosis and treatment.

Moreover, the region benefits from robust R&D activity; for instance, leading players like Grifols and Sobi have expanded their focus on recombinant antithrombin development. The U.S. FDA's orphan drug designation for antithrombin therapies further encourages innovation through incentives. Additionally, rising utilization during surgeries and organ transplants at top-tier hospitals, including the Mayo Clinic and the Cleveland Clinic, boosts demand. North America’s strong healthcare infrastructure and favorable reimbursement policies position the region as a key market for continued expansion.

Key Highlights

• The global antithrombin market size was valued at USD 422.32 million in 2024 and is estimated to grow from USD 443.23 million in 2025 to reach USD 652.35 million by 2033, growing at a CAGR of 4.95% during the forecast period (2025–2033).
• The global antithrombin market is segmented by source into human and recombinant goat milk.
• By dosage form, the market is categorized into lyophilized powder and liquid form.
• Based on application, the market is divided into therapeutics, research, diagnostics, and others.
• By end user, the market includes hospitals, specialty clinics, academic & research institutes, diagnostic laboratories, and others.
• North America is the highest shareholder in the global market.

Market Segments

1. By Source
   1. Human
   2. Recombinant Goat Milk
2. By Dosage Form
   1. Lyophilized Powder
   2. Liquid Form
3. By Application
   1. Therapeutics
   2. Research
   3. Diagnostics
   4. Others
4. By End User
   1. Hospitals
   2. Specialty Clinics
   3. Academic & Research Institutes
   4. Diagnostic Laboratories
   5. Others
5. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Latin America
   5. The Middle East and Africa